Article
Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.
The Journal of allergy and clinical immunology - 1 Feb 2018
Leiding Jennifer W, Okada Satoshi, Hagin David, Abinun Mario, Shcherbina Anna, Balashov Dmitry N, Kim Vy H D, Ovadia Adi, Guthery Stephen L, Pulsipher Michael, Lilic Desa, Devlin Lisa A, Christie Sharon, Depner Mark, Fuchs Sebastian, van Royen-Kerkhof Annet, Lindemans Caroline, Petrovic Aleksandra, Sullivan Kathleen E, Bunin Nancy, Kilic Sara Sebnem, Arpaci Fikret, Calle-Martin Oscar de la, Martinez-Martinez Laura, Aldave Juan Carlos, Kobayashi Masao, Ohkawa Teppei, Imai Kohsuke, Iguchi Akihiro, Roifman Chaim M, Gennery Andrew R, Slatter Mary, Ochs Hans D, Morio Tomohiro, Torgerson Troy R
Abstract excerpt
BACKGROUND: Gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) cause susceptibility to a range of infections, autoimmunity, immune dysregulation, and combined immunodeficiency. Disease manifestations can be mild or severe and life-threatening. Hematopoietic stem cell transplantation (HSCT) has been used in some patients with more severe symptoms to treat and cure the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
